Cardiovascular Disease

Vericiguat (Standard) is the analytical standard of Vericiguat. This product is intended for research and analytical applications. Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.

Perhexiline (maleate) (Standard) is the analytical standard of Perhexiline (maleate). This product is intended for research and analytical applications. Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina.

Bamifylline hydrochloride is a drug in the chemical class of xanthine that acts as a selective adenosine A1 receptor antagonist.

Dimethylsildenafil is a derivative of Sildenafil (HY-15025). Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

ONO-7300243 (Standard) is the analytical standard of ONO-7300243 (HY-100882). This product is intended for research and analytical applications. ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.

Droxicainide is an antiarrhythmic agent.

Hidrosmin (mixture) (Standard) is the analytical standard of Hidrosmin (mixture) (HY-105946A). This product is intended for research and analytical applications. Hidrosmin (mixture) is a mixture of 3,5-di-O-(hydroxyethyl)diosmin and 3'-mono-O-(hydroxyethyl)diosmin.

Nilvadipine (Standard) is the analytical standard of Nilvadipine. This product is intended for research and analytical applications. Nilvadipine is a potent calcium channel antagonist, and the IC₅₀ value is around 0.1 nM.

Luminacin G1 has a strong inhibitory effect on capillary formation (IC₅₀ is less than 0.1 μg/mL).

D-NAME (NG-Nitro-D-arginine methyl ester) is an orally active enantiomer of L-NAME (HY-18729). D-NAME inhibits Nitric oxide synthase activity in myocardium and aorta (Note: D-NAME was once classified as an inactive substance and used as a negative control in nitric oxide synthase inhibition studies), induces increases in systolic blood pressure and mean arterial blood pressure, reduces mesenteric arterial conductance, elevates the ratio of left ventricular weight to body weight, induces myocardial fibrosis, increases the cross-sectional area of aortic wall, enhances mesenteric vasodilation induced by nitrovasodilators, and releases nitric oxide via its guanidino nitro group. D-NAME has no effect on ovalbumin-induced pulmonary eosinophilia in sensitized mice. D-NAME can be used in hypertension-related research.

Mozavaptan (Standard) is the analytical standard of Mozavaptan. This product is intended for research and analytical applications. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.

Sitaxsentan (sodium) (Standard) is the analytical standard of Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) (HY-11103). This product is intended for research and analytical applications. Sitaxsentan sodium is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan sodium exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.

UR-7247 is a potent and orally active angiotensin II AT1 receptor antagonist. UR-7247 decreases arterial pressure and increases renal blood flow.

Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a K_d value of 148 nM.

Lomitapide (Standard) is the analytical standard of Lomitapide. This product is intended for research and analytical applications. Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.

Ramipril diketopiperazine is an impurity in the ACE inhibitor Ramipril (HY-B0279).

Sulcardine hydrochloride is a multi-ion channel blocker that can reduce I_Na and I_Ca with IC₅₀ values of 26.9 µM and 69.2 µM, respectively. Sulcardine hydrochloride is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine hydrochloride has anti-arrhythmic effects.

ε-Biotinamidocaproyl-β-alanyl-β-alanyl-lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. Structurally, ε-Biotinamidocaproyl-β-alanyl-β-alanyl-lisinopril is a biotinylated derivative of lisinopril (HY-18206), with a chemical structure linking the biotin molecule and the lisinopril molecule composed of 19 atoms. ε-Biotinamidocaproyl-β-alanyl-β-alanyl-lisinopril can bind to both ACE and streptavidin (HY-P3152) simultaneously, making it possible to separate and purify ACE using streptavidin-agarose beads.

GRL-098-22 (Compound 6t) is a potent inhibitor targeting G protein-coupled receptor kinase 5 (GRK5) and GRK6 with IC₅₀ values of 0.6 μM and 0.19 μM, respectively. GRL-098-22 is promising for research of diseases such as heart failure and multiple myeloma.

CGS 13928C (Wy-44655) is an angiotensin-converting enzyme (ACE) inhibitor. CGS 13928C effectively inhibits the pressor and blood pressure responses induced by exogenous angiotensin I by blocking the renin-angiotensin system. CGS 13928C exhibits dose-dependent hypotensive activity.